Key industry updates highlight ongoing financial activities and regulatory decisions shaping biotech’s trajectory. Thermo Fisher inaugurated a new carbon-neutral manufacturing center in North Carolina, underpinning U.S. life sciences production. Illumina's CEO remains optimistic about stable growth despite geopolitical and funding headwinds. Meanwhile, bio/pharma IPOs approach cautiously amidst market uncertainty. Regulatory shifts include expanded FDA daily adverse event data publishing and accelerated action on novel immunotherapies.